Public Service Enterprise Group Incorporated (PEG)
NYSE: PEG · Real-Time Price · USD
81.12
-0.61 (-0.75%)
Sep 5, 2025, 4:00 PM - Market closed
PEG Revenue
Public Service Enterprise Group had revenue of $2.81B in the quarter ending June 30, 2025, with 15.77% growth. This brings the company's revenue in the last twelve months to $11.13B, up 8.69% year-over-year. In the year 2024, Public Service Enterprise Group had annual revenue of $10.29B, down -8.43%.
Revenue (ttm)
$11.13B
Revenue Growth
+8.69%
P/S Ratio
3.63
Revenue / Employee
$853,376
Employees
13,047
Market Cap
40.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.29B | -947.00M | -8.43% |
| Dec 31, 2023 | 11.24B | 1.44B | 14.66% |
| Dec 31, 2022 | 9.80B | 78.00M | 0.80% |
| Dec 31, 2021 | 9.72B | 119.00M | 1.24% |
| Dec 31, 2020 | 9.60B | -473.00M | -4.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Duke Energy | 30.85B |
| The Southern Company | 28.36B |
| NextEra Energy | 25.90B |
| Constellation Energy | 24.82B |
| Exelon | 23.77B |
| National Grid | 23.74B |
| American Electric Power Company | 20.67B |
| Vistra | 18.51B |
PEG News
- 5 days ago - Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis - GlobeNewsWire
- 5 days ago - Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis - GlobeNewsWire
- 17 days ago - Public Service Enterprise: Long-Term Earnings Outlook Remains Very Positive - Seeking Alpha
- 24 days ago - Three Stocks Morgan Stanley Recommends for Playing the ‘Nuclear Renaissance' - Investopedia
- 4 weeks ago - Public Service Enterprise Group Incorporated (PEG) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - PSEG ANNOUNCES SECOND QUARTER 2025 RESULTS - PRNewsWire
- 4 weeks ago - PSE&G Energy Efficiency Programs Deliver Nearly $720 Million in Annual Utility Bill Savings and Additional $740 Million in Rebate Savings to New Jersey Customers - PRNewsWire
- 5 weeks ago - PSEG recommends shareholders reject "mini-tender" offer by TRC Capital Investment Corporation - PRNewsWire